PTC Therapeutics, Inc. (PTCT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$69.30-2.94%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · PTCT
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||
| Revenues | 1,008.8 | 1,730.7 | 806.8 | 937.8 | 698.8 | 538.6 | 380.8 | 307.0 | 264.7 | 194.4 | 82.7 | 36.8 | 25.2 | 34.7 |
| Total Revenues | — | — | — | — | — | — | — | — | 264.7 | 194.4 | 82.7 | 36.8 | 25.2 | 34.7 |
| Cost of Revenues | — | — | — | — | — | — | — | 12.1 | — | — | — | — | — | — |
| Operating Expenses & Income | ||||||||||||||
| Selling, General & Admin | 347.7 | 347.1 | 300.9 | 332.5 | 326.0 | 285.8 | 245.2 | 202.5 | 153.5 | — | — | — | — | — |
| R&D Expenses | 433.3 | 455.2 | 534.5 | 666.6 | 651.5 | 540.7 | 477.6 | 257.5 | 172.0 | 117.5 | 117.6 | 121.8 | 79.8 | 54.9 |
| Operating Income | 125.6 | 866.9 | (302.6) | (439.5) | (447.4) | (374.4) | (431.8) | (241.2) | (115.7) | (64.3) | (132.1) | (167.1) | (99.4) | (45.4) |
| Earnings from Continuing Operations | ||||||||||||||
| Asset Writedown | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EBT, Incl. Unusual Items | (67.1) | 696.6 | (363.1) | (696.1) | (587.5) | (518.3) | (402.9) | (239.9) | (128.1) | (77.7) | (141.5) | (170.0) | (98.4) | (51.6) |
| Income Tax Expense | (28.7) | 14.0 | 0.2 | (69.5) | (28.5) | 5.6 | 35.2 | 11.7 | (0.0) | 1.3 | 0.6 | 0.5 | (4.7) | (2.3) |
| Net Income | ||||||||||||||
| Net Income | (38.0) | 682.6 | (363.3) | (626.6) | (559.0) | (523.9) | (438.2) | (251.6) | (128.1) | (79.0) | (142.1) | (170.4) | (93.8) | (51.6) |
| Per Share | ||||||||||||||
| Basic EPS | (0.46) | 8.58 | (4.73) | (8.37) | (7.79) | (7.43) | (6.64) | (4.27) | — | — | — | — | (2.97) | (5.18) |
| Diluted EPS | (0.41) | 7.78 | (4.73) | (8.37) | (7.79) | (7.43) | (6.64) | — | — | — | — | — | (2.97) | (5.18) |
| Revenue per Share | 10.96 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 83.0 | 79.5 | 76.8 | 74.8 | 71.7 | 70.5 | 66.0 | — | — | — | — | — | 31.6 | 12.8 |
| Diluted Weighted Avg Shares | 92.0 | 88.3 | 76.8 | 74.8 | 71.7 | 70.5 | 66.0 | — | — | — | — | — | 31.6 | 12.8 |
| Supplemental | ||||||||||||||
| EBITDA | — | 905.8 | (226.9) | (202.9) | (318.6) | (310.3) | (388.3) | (209.0) | (89.6) | (46.6) | — | — | — | — |
| EBIT | 125.6 | 866.9 | (302.6) | (439.5) | (447.4) | (374.4) | (431.8) | (241.2) | (115.7) | (64.3) | (132.1) | (167.1) | (99.4) | (45.4) |
| Effective Tax Rate | 42.8% | — | — | 10.0% | 4.8% | -1.1% | -8.7% | -4.9% | 0.0% | -1.7% | -0.4% | -0.3% | 4.8% | 4.5% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.